Growth Metrics

Nautilus Biotechnology (NAUT) Gains from Investment Securities (2021 - 2024)

Nautilus Biotechnology has reported Gains from Investment Securities over the past 4 years, most recently at -$84000.0 for Q4 2024.

  • Quarterly results put Gains from Investment Securities at -$84000.0 for Q4 2024, up 98.9% from a year ago — trailing twelve months through Dec 2024 was -$84000.0 (changed N/A YoY), and the annual figure for FY2024 was -$84000.0, changed.
  • Gains from Investment Securities reached -$84000.0 in Q4 2024 per NAUT's latest filing, up from -$7.6 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $26.3 million in Q4 2021 and bottomed at -$7.6 million in Q4 2023.
  • Median Gains from Investment Securities over the past 4 years was $1.7 million (2022), compared with a mean of $5.6 million.
  • The largest annual shift saw Gains from Investment Securities tumbled 551.6% in 2023 before it skyrocketed 98.9% in 2024.
  • Over 4 years, Gains from Investment Securities stood at $26.3 million in 2021, then crashed by 93.58% to $1.7 million in 2022, then crashed by 551.6% to -$7.6 million in 2023, then surged by 98.9% to -$84000.0 in 2024.
  • Business Quant data shows Gains from Investment Securities for NAUT at -$84000.0 in Q4 2024, -$7.6 million in Q4 2023, and $7.6 million in Q1 2023.